SCHEMBL21392342

SCHEMBL21392342

CC(C)(C)c1ccc(Nc2ccccc2O)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B2 P37059 2/20 0.55
UQCRB P14927 1/20 0.55
CXCR2 P25025 1/20 0.46
LMNA P02545 1/20 0.43
TYR P14679 1/20 0.43
AKR1C3 P42330 2/20 0.43
AKR1C2 P52895 2/20 0.43
PSD A5PKW4 1/20 0.43
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
ALDH1A1 P00352 3/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
NPC1 O15118 1/20 0.41
GLA P06280 1/20 0.41
RAB9A P51151 1/20 0.41
ATM Q13315 1/20 0.41
TSHR P16473 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
HSD11B1 P28845 1/20 0.41
HSD17B3 P37058 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17546531 0.86 AKR1C3 (0.45) HSD17B2UQCRBLMNATYRAKR1C3
SCHEMBL1920750 0.84 CXCR2 (0.59) CXCR2LMNACA2ALDH1A1L3MBTL1
SCHEMBL9703296 0.79 P2RY1 (0.42) HSD17B2UQCRBAKR1C3AKR1C2CA1
SCHEMBL4901952 0.79 P2RX7 (0.46) AKR1C3AKR1C2ALDH1A1NPC1RAB9A
SCHEMBL22914813 0.79 ALDH1A1 (0.50) HSD17B2UQCRBCXCR2AKR1C3AKR1C2
SCHEMBL30686692 0.79 MAPT (0.60) CXCR2LMNAALDH1A1L3MBTL1NPC1
SCHEMBL5823760 0.79 MAPT (0.60) CXCR2LMNAALDH1A1L3MBTL1NPC1
SCHEMBL1921886 0.78 CXCR2 (0.53) CXCR2LMNAAKR1C3CA2ALDH1A1
SCHEMBL6760764 0.78 MAPT (0.55) CXCR2LMNAALDH1A1NPC1GLA
SCHEMBL11000813 0.78 CXCR2 (0.63) CXCR2LMNAALDH1A1L3MBTL1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10886477-B2 Iridium complex and organic electroluminescence device using the same UDC IRELAND LIMITED (IE) 2021-01-05 US disclosed
US-20190296251-A1 IRIDIUM COMPLEX AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME LUMINESCENCE TECHNOLOGY CORPORATION (TW) 2019-09-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190296251-A1 IRIDIUM COMPLEX AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME IMPA1, LAGE3, OCIAD1 HSD17B2 2059/4885UQCRB 1722/4885CXCR2 3496/4885
US-10886477-B2 Iridium complex and organic electroluminescence device using the same IMPA1, LAGE3, OCIAD1 HSD17B2 2059/4885UQCRB 1722/4885CXCR2 3496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.